HAE's Investor Series invites a variety of investors for an interactive forum to share what their perspectives on what investors are looking for, funding trends, strategies, insights as well as answer your questions.

Session focus: Early stage & seed stage capital

Investors Series is a live Q&A. Attendees are invited to submit their questions ahead of time.

Space is limited.

The HAE investor Series is exclusively for HAE members

COVID-19 has sharpened the focus on healthcare in a number of ways. Join us for an exclusive conversation with Amy Schulman to learn about how to position your startup to investors and the trends investors are looking to invest in. 

Amy Schulman will be discussing her professional trajectory, advice for healthcare companies and her perspective on the current state of the biotech industry. Learn more about Polaris Partners at https://www.polarispartners.com . 

Featured Investor

Amy Schulman is a managing partner at Polaris Partners and focuses on start-up investments in healthcare companies. She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also represents Polaris as a director of Cyclerion (NASDAQ: CYCN), Dewpoint Therapeutics, Kallyope, Volastra, Thirty Madison and ByHeart. Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also co-founded the LS Polaris Innovation Fund which was formed in 2017. Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. After its sale, Schulman became the president of Pfizer Consumer Healthcare. 

Schulman has received numerous awards including Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY), and Mount Sinai Hospital in New York City. 

She is a Phi Beta Kappa graduate of Wesleyan University who earned her J.D. from Yale Law School.

Please note that registration for this event closes 1 hour prior to the start of the session.